<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04257175</url>
  </required_header>
  <id_info>
    <org_study_id>6482-19-SMC</org_study_id>
    <nct_id>NCT04257175</nct_id>
  </id_info>
  <brief_title>CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression</brief_title>
  <official_title>Giving CAR-T CD19 Transgenic T Cells for Acute Myeloid Leukemia Patients (AML) With t 8:21 and CD19 Expression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chimeric antigen receptor (CAR-T) engineered T cells against the CD19 protein have been shown&#xD;
      to be effective against acute lymphoma and lymphocytic leukemia and are approved by the US&#xD;
      (FDA), European (EMA) and Health Basel.&#xD;
&#xD;
      However, little information exists on using CD19CAR for treatment of recurrent or&#xD;
      irresponsible to previous treatment acute myeloid leukemia.&#xD;
&#xD;
      The proposed study will include patients with recurrent disease or those with disease&#xD;
      irresponsible to common treatments and they will be treated with CAR-T CD19.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 18, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in the peripheral blood counts and differential</measure>
    <time_frame>Within two years from the introduction of the CAR-T CD19</time_frame>
    <description>Will be evaluated by Coulter counter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change in the antigen expression on the leukemic blasts</measure>
    <time_frame>Within two years from the introduction of the CAR-T CD19</time_frame>
    <description>Will be evaluated by FACS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change in the measurable residual disease</measure>
    <time_frame>Within two years from the introduction of the CAR-T CD19</time_frame>
    <description>Will be evaluated by PCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change in the chromosomal translocations and aberrations</measure>
    <time_frame>Within two years from the introduction of the CAR-T CD19</time_frame>
    <description>Will be evaluated by cytogenetics and FISH</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Cyclophosphamide, Flodarabine,CAR-T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The appropriate participants will undergo lymhopheresis to collect lymphocytes from PBMC peripheral blood. CAR T CD19 cells will be produced. The participants will receive cyclophosphamide 300 mg / m² and flodarabine 30 mg / m² lymphodeplition intravenously daily for 3 days.&#xD;
The CAR-T CD19 cells will be given on the 5 to 7 day post lymphodeplition .</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAR-T CD19</intervention_name>
    <description>The CAR-T infusion will be given in IV infusion. The target dose is 1 X 106 positive CAR / kg T cells (range: 0.5-1.5X 106 CAR / kg positive T cells).</description>
    <arm_group_label>Cyclophosphamide, Flodarabine,CAR-T cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with recurrent acute myeloid leukemia (AML) including those after bone marrow&#xD;
             transplantation or not responding to previous therapy, who have exhausted other&#xD;
             approved relevant therapies such as chemotherapy protocols that are ineffective and&#xD;
             with high toxicity, or FLT3 inhibitors in patients with FLT3 .&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Heart disease including severe heart failure (NYHA III-IV), recent MI or CABG surgery&#xD;
             (in previous six months), severe ventricular rhythm abnormalities, non ischemic heart&#xD;
             disease, LVEF less than 45%&#xD;
&#xD;
          -  Active involvement of CNS&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Graft versus host disease III-IV grade - Stroke or seizure in the last six months&#xD;
             before treatment&#xD;
&#xD;
          -  A positive result for the HIV infection (serum)&#xD;
&#xD;
          -  Active hepatitis infection&#xD;
&#xD;
          -  Life-threatening allergies to cyclophosphamide or fludarabine&#xD;
&#xD;
          -  No informed consent signed by candidate&#xD;
&#xD;
          -  Candidate enrolled in other study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Arnon Nagler, MD</last_name>
    <phone>+972-3-530 5830</phone>
    <email>Arnon.Nagler@sheba.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>57261</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnon Nagler, M.D.</last_name>
    </contact>
    <contact_backup>
      <last_name>M.D.</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 20, 2020</study_first_submitted>
  <study_first_submitted_qc>February 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Prof Arnon Nagler</investigator_full_name>
    <investigator_title>M.D., M.Sc, Professor of Medicine Tel Aviv University, Director Hematology Division, Chaim Sheba Medical Center</investigator_title>
  </responsible_party>
  <keyword>Chimeric antigen receptors; Mixed phenotype acute leukemia; T cells.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

